Patients on anticoagulants/antiplatelets
Dental riskhigh
Antiplatelets (aspirin, clopidogrel, prasugrel, ticagrelor) reduce platelet aggregation. Anticoagulants (warfarin/VKA; DOACs: apixaban, rivaroxaban, dabigatran, edoxaban) reduce clotting pathway activity. CORE DENTAL PRINCIPLE: For most patients and most dental procedures, you do NOT stop anticoagulants/antiplatelets — you control bleeding locally. Interrupting therapy carries real thrombotic risk (stroke, MI, stent thrombosis) that outweighs dental bleeding risk.
The full condition entry includes
- Safe vs avoid lists: antibiotics, analgesics, local anesthetics
- Vasoconstrictor limits and treatment modifications
- Pre/intra/post-op monitoring and deferral criteria
- Emergency management, explained for study
More medical conditions in dentistry
Hypertension (uncontrolled / hypertensive urgency)Ischemic heart disease (stable angina, recent/old MI)Heart failure (compensated vs decompensated)Valvular heart disease / Prosthetic heart valvesCongenital heart disease (high-risk lesions/repairs)Pulmonary hypertensionCOPD (moderate-severe; oxygen dependence)Active upper respiratory infection (URI)Chronic hypoxemia / home oxygen patientsInterstitial lung disease / pulmonary fibrosisStroke / TIA historyMyasthenia gravis
Dentalverse is an educational resource for dental students and dentists. This page is a study reference — it is not medical advice and does not replace clinical judgment. Always follow your institution's protocols and your supervisor's guidance.